Roger S. McIntyre, MD, FRCPC
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Ontario, Canada.
Commentary
Prescribing GLP-1 Receptor Agonists for Persons With Mental Disorders: Evidence-Based and Aspirational Targets
June 1, 2026
Evidence-based prescription of GLP-1 RAs in persons with serious mental illness and/or substance use disorders holds promise to improve their health and wellbeing and possibly reduce excess mortality.
Commentary
Practitioners Providing Care for Persons with Severe Mental Disorders Should Routinely Screen for Metabolic Dysfunction–Associated Steatotic Liver Disease
September 10, 2025
Persons with severe mental illnesses should be routinely screened for MASLD as part of a psychiatric and medical assessment that includes social and economic determinants of health, risk factors...
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
July 7, 2025
The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.
Academic Highlights
Dysregulation of Noradrenergic Activity
November 8, 2024
Dysregulation of noradrenergic activity plays a key role in symptom presentation in major depressive disorder, schizophrenia, Alzheimer’s agitation, and PTSD. This article provides an expert panel’s consensus regarding the...
